Raymond James Financial Inc. Makes New $798,000 Investment in Savara Inc (NASDAQ:SVRA)

Raymond James Financial Inc. acquired a new stake in Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 259,798 shares of the company’s stock, valued at approximately $798,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Cibc World Markets Corp bought a new stake in Savara in the fourth quarter worth approximately $33,000. KLP Kapitalforvaltning AS acquired a new position in shares of Savara during the 4th quarter valued at $41,000. Virtu Financial LLC bought a new position in Savara during the third quarter worth $67,000. China Universal Asset Management Co. Ltd. grew its holdings in Savara by 14.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after purchasing an additional 4,732 shares during the period. Finally, SG Americas Securities LLC grew its holdings in Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock worth $158,000 after purchasing an additional 6,330 shares during the period. Institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ SVRA opened at $3.00 on Wednesday. The company has a market cap of $518.24 million, a P/E ratio of -6.98 and a beta of 0.44. The company has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $3.05. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The firm had revenue of $0.27 million for the quarter. Sell-side analysts predict that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Savara in a research report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.